Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.12 |
| Open | 7.01 |
| 1-Year Change | 13.8% |
| Day's Range | 6.92 - 7.28 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 7.24 | 0.11 | 1.54% | 7.13 | 7.28 | 6.78 |
| Nov 14, 2024 | 7.14 | -0.65 | -8.34% | 7.79 | 7.89 | 7.01 |
| Nov 13, 2024 | 7.64 | -0.68 | -8.17% | 8.32 | 8.51 | 7.64 |
| Nov 12, 2024 | 8.27 | -0.72 | -8.01% | 8.99 | 9.40 | 7.57 |
| Nov 11, 2024 | 8.97 | 0.07 | 0.79% | 8.90 | 10.63 | 8.86 |
| Nov 8, 2024 | 8.88 | -0.29 | -3.16% | 9.17 | 9.20 | 8.80 |
| Nov 7, 2024 | 9.12 | 0.17 | 1.90% | 8.95 | 9.29 | 8.84 |
| Nov 6, 2024 | 8.86 | -0.08 | -0.89% | 8.94 | 9.22 | 8.38 |
| Nov 5, 2024 | 8.87 | -0.17 | -1.88% | 9.04 | 9.43 | 8.54 |
| Nov 4, 2024 | 9.03 | -0.29 | -3.11% | 9.32 | 9.32 | 8.85 |
| Nov 1, 2024 | 9.32 | -0.34 | -3.52% | 9.66 | 9.81 | 9.25 |
| Oct 31, 2024 | 9.52 | -0.19 | -1.96% | 9.71 | 9.86 | 9.47 |
| Oct 30, 2024 | 9.79 | -0.26 | -2.59% | 10.05 | 10.08 | 9.67 |
| Oct 29, 2024 | 10.03 | -0.14 | -1.38% | 10.17 | 10.59 | 9.83 |
| Oct 28, 2024 | 10.10 | 0.36 | 3.70% | 9.74 | 10.43 | 9.68 |
| Oct 25, 2024 | 9.72 | -0.17 | -1.72% | 9.89 | 9.93 | 9.49 |
| Oct 24, 2024 | 9.87 | -0.11 | -1.10% | 9.98 | 10.11 | 9.81 |
| Oct 23, 2024 | 9.92 | -0.08 | -0.80% | 10.00 | 10.19 | 9.88 |
| Oct 22, 2024 | 10.03 | 0.04 | 0.40% | 9.99 | 10.31 | 9.95 |
| Oct 21, 2024 | 10.07 | -0.02 | -0.20% | 10.09 | 10.18 | 9.86 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com